Enliven Financial Statements From 2010 to 2024

ELVN Stock   25.41  1.06  4.35%   
Enliven Therapeutics financial statements provide useful quarterly and yearly information to potential Enliven Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Enliven Therapeutics financial statements helps investors assess Enliven Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Enliven Therapeutics' valuation are summarized below:
Market Capitalization
1.2 B
Earnings Share
(1.89)
We have found one hundred twelve available fundamental signals for Enliven Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Enliven Therapeutics' prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 87.7 M, Research Development of 67.8 M or Total Operating Expenses of 87.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.1. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Enliven Therapeutics Correlation against competitors.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

Enliven Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets285.5 M271.9 M67.2 M
Slightly volatile
Short and Long Term Debt Total253.1 K335 K444.3 K
Slightly volatile
Other Current Liabilities26.3 M25 M4.5 M
Slightly volatile
Total Current Liabilities27.2 M25.9 M5.5 M
Slightly volatile
Accounts Payable505.4 K532 K921.2 K
Slightly volatile
Cash68.8 M100.1 M38.3 M
Slightly volatile
Cash And Short Term Investments265.8 M253.1 M63.2 M
Slightly volatile
Common Stock Shares Outstanding37.3 M35.5 M8.9 M
Slightly volatile
Liabilities And Stockholders Equity285.5 M271.9 M67.2 M
Slightly volatile
Non Current Liabilities Total63.6 K67 K32.6 M
Slightly volatile
Other Current Assets13.7 M13 M2.4 M
Slightly volatile
Other Stockholder Equity420.2 M400.2 M58.3 M
Slightly volatile
Total Liabilities24.7 M26 M35.8 M
Slightly volatile
Total Current Assets279.5 M266.2 M65.6 M
Slightly volatile
Common Stock43 K41 K8.5 K
Slightly volatile
Property Plant And Equipment Net965.8 K1.1 M622.3 K
Slightly volatile
Non Current Assets Total3.7 M5.7 MM
Slightly volatile
Other Liabilities64 K72 K78.4 K
Slightly volatile
Current Deferred Revenue3.2 M6.3 M1.5 M
Slightly volatile
Capital Lease Obligations253.6 K335 K148.4 K
Slightly volatile
Property Plant And Equipment Gross1.4 M1.7 M749.2 K
Slightly volatile
Capital Stock43 K41 K6.5 K
Slightly volatile
Non Current Liabilities Other63.6 K67 K158.9 K
Slightly volatile
Net Working Capital149.1 M240.3 M132.2 M
Pretty Stable
Short Term Debt253.6 K335 K148.4 K
Slightly volatile
Property Plant Equipment753.5 K1.1 M555.6 K
Slightly volatile
Deferred Long Term Liabilities1.3 M1.5 M1.6 M
Slightly volatile

Enliven Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses87.7 M83.5 M23.3 M
Slightly volatile
Research Development67.8 M64.6 M18.8 M
Slightly volatile
Total Operating Expenses87.7 M83.5 M23.3 M
Slightly volatile
Selling General Administrative19.9 M19 M5.3 M
Slightly volatile
Selling And Marketing Expenses22.9 M21.8 M6.8 M
Slightly volatile
Cost Of Revenue252.6 K297 K113.2 K
Slightly volatile
Net Interest Income12.6 M12 M1.7 M
Slightly volatile
Interest Income12.6 M12 M1.7 M
Slightly volatile
Reconciled Depreciation184.8 K297 K87.1 K
Slightly volatile
Interest Expense720.5 K1.4 M296.9 K
Slightly volatile

Enliven Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow54.9 M75.6 M30.4 M
Slightly volatile
End Period Cash Flow68.9 M100.2 M38.3 M
Slightly volatile
Stock Based Compensation13.6 M12.9 M2.5 M
Slightly volatile
Depreciation155.1 K297 K77.1 K
Slightly volatile
Change To Operating Activities1.2 M2.1 M677 K
Slightly volatile
Issuance Of Capital Stock505.3 K531.9 K95.9 M
Slightly volatile
Change To Netincome1.6 M1.7 M7.7 M
Slightly volatile
Change To Liabilities1.1 MM651.8 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.480.50173.8772
Slightly volatile
Payables Turnover0.590.55830.1125
Slightly volatile
Cash Per Share11.257.12178.354
Slightly volatile
Days Payables Outstanding62165413.3 K
Slightly volatile
Income Quality0.620.85590.7634
Pretty Stable
Current Ratio17.1110.278516.8997
Pretty Stable
Graham Number29.5617.704822.8323
Slightly volatile
Capex Per Share0.0040.00420.0391
Pretty Stable
Interest Debt Per Share0.120.140.1497
Slightly volatile
Debt To Assets0.05170.05810.0633
Slightly volatile
Days Of Payables Outstanding62165413.3 K
Slightly volatile
Quick Ratio17.1110.278516.8997
Pretty Stable
Net Income Per E B T0.80.90.9789
Slightly volatile
Cash Ratio3.673.867314.7675
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00241.018
Slightly volatile
Debt Ratio0.05170.05810.0633
Slightly volatile

Enliven Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap516.6 M492 M306 M
Pretty Stable
Enterprise Value411.8 M392.2 M186.8 M
Pretty Stable

Enliven Fundamental Market Drivers

Cash And Short Term Investments253.1 M

Enliven Upcoming Events

9th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Enliven Therapeutics Financial Statements

Enliven Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue6.3 M3.2 M
Cost Of Revenue297 K252.6 K

Pair Trading with Enliven Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Enliven Stock

  0.46HLN Haleon plcPairCorr
  0.44ANRO Alto Neuroscience,PairCorr
  0.42BA Boeing Fiscal Year End 29th of January 2025 PairCorr
  0.4SHG Shinhan FinancialPairCorr
  0.37JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:
Check out the analysis of Enliven Therapeutics Correlation against competitors.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.89)
Return On Assets
(0.21)
Return On Equity
(0.31)
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.